13F Holdings
中文EN

DYN Dyne Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—

Leverage & solvency

Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$398.33M$281.41M$210.76M$142.76M$121.31M
SG&A expense$69.85M$62.48M$31.40M$28.20M$28.72M
Operating income-$468.18M-$343.89M-$242.16M-$170.96M-$150.03M
Income tax$0$0$0——
Net income-$446.21M-$317.42M-$235.94M-$168.10M-$149.29M
EBITDA-$466.13M-$342.21M-$240.49M-$169.28M-$148.94M
EPS (basic)-3.47-3.37-3.95-3.23-2.93
EPS (diluted)-3.47-3.37-3.95-3.23-2.93
Weighted avg. shares (diluted)————50.90M
Balance sheet
Cash & equivalents$893.37M$435.45M$121.63M$172.15M$200.82M
Short-term investments$217.19M$206.82M$1.47M$83.86M$175.75M
Current assets$1.13B$659.28M$129.38M$265.59M$382.39M
PP&E, net$24.03M$5.40M$4.78M$5.95M$4.68M
Total assets$1.19B$691.23M$165.08M$306.32M$425.66M
Current liabilities$50.62M$42.26M$51.09M$28.09M$28.72M
Long-term debt$148.92M$0———
Total debt$148.92M$0———
Total liabilities$214.83M$61.40M$73.79M$53.96M$57.47M
Shareholders' equity$972.13M$629.84M$91.29M$252.36M$368.20M
Net debt-$744.45M-$435.45M———
Shares outstanding164.95M102.32M61.47M55.64M51.57M
Cash flow statement
Operating cash flow-$403.21M-$292.37M-$188.16M-$153.65M-$119.56M
Capital expenditure$1.92M$2.38M$729,000$3.07M$3.62M
Free cash flow-$405.13M-$294.75M-$188.89M-$156.71M-$123.18M
Investing cash flow-$28.75M-$204.08M$83.31M$87.20M-$137.89M
Financing cash flow$890.31M$809.89M$54.32M$37.39M$157.82M
Depreciation & amortization$2.05M$1.67M$1.67M$1.68M$1.09M
Stock-based compensation$45.85M$45.86M$19.97M$15.18M$17.54M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.